AngioDynamics (NASDAQ: ANGO) grants RSUs and performance rights to legal chief
Rhea-AI Filing Summary
Weiss Lawrence T reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics SVP and Chief Legal Officer Lawrence T. Weiss received equity-based compensation on July 15, 2026. He was granted 21,288 restricted stock units, each representing a contingent right to one share of common stock, plus 21,288 performance rights, also initially tied one-for-one to common shares.
The restricted stock units vest in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. The performance rights are earned over a three-year performance period based on total shareholder return versus a peer group, with a potential payout from 0% up to 240% of the 21,288-share target; any unearned awards are forfeited. Following these grants, Weiss directly holds 112,618 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 21,288 shares
Net Buy
2 txns
Insider
Weiss Lawrence T
Role
SVP, Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Right F2 | 21,288 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 21,288 | $0.00 | $0.00 |
Holdings After Transaction:
Performance Right — 21,288 shares (Direct);
Common Stock — 112,618 shares (Direct)
Footnotes (2)
- F1. The acquisition of 21,288 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,288 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
- F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
Key Figures
Restricted stock units granted: 21,288 shares
Performance rights target: 21,288 rights
Performance rights maximum payout: 240% of target
+2 more
5 metrics
Restricted stock units granted
21,288 shares
Granted to Lawrence T. Weiss on July 15, 2026; vest in four equal annual installments from July 15, 2027 to July 15, 2030.
Performance rights target
21,288 rights
Each performance right initially represents a contingent right to receive one share of common stock.
Performance rights maximum payout
240% of target
Based on total shareholder return versus a peer group over a three-year performance period, including a potential 20% adjustment.
Post-grant common stock holdings
112,618 shares
Direct common stock ownership of Lawrence T. Weiss after the July 15, 2026 restricted stock unit grant.
Grant price per share
$0.0000
Reported transaction price per share for both the restricted stock units and performance rights awards.
Key Terms
restricted stock units, performance right, total shareholder return
3 terms
restricted stock units financial
"represents 21,288 restricted stock units, each of which represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance right financial
"Each performance right represents a contingent right to receive one share"
FAQ
What equity awards did AngioDynamics (ANGO) grant to Lawrence T. Weiss?
AngioDynamics granted 21,288 restricted stock units and 21,288 performance rights to SVP and Chief Legal Officer Lawrence T. Weiss on July 15, 2026, with each unit or right initially linked to one share of common stock.
How do the restricted stock units awarded to AngioDynamics (ANGO) executive Weiss vest?
The 21,288 restricted stock units vest in four equal annual installments. Vesting occurs 25% each on July 15 of 2027, 2028, 2029 and 2030, contingent on continued service and the award terms remaining in effect.
What performance conditions apply to the AngioDynamics (ANGO) performance rights granted to Weiss?
Each performance right is tied to total shareholder return versus a peer group over a three-year period. Between 0% and 200% of the 21,288-share target can be earned, with a possible 20% upward or downward adjustment, for up to 240% of target.
What is the potential maximum payout from AngioDynamics (ANGO) performance rights to Weiss?
The performance rights allow a maximum payout of 240% of the 21,288-share target. This results from TSR-based achievement between 0% and 200% plus a potential 20% adjustment, with any unearned portion forfeited after the performance period.
Were the AngioDynamics (ANGO) equity grants to Weiss made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. The equity reported consists of compensation grants (restricted stock units and performance rights), rather than open-market purchases or sales under a trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
